S. Tacar

Next generation sequencing analysis of BRCA1 and BRCA2 identifies novel variations in breast cancer.

H. Tozkır, O. Avci, E. Şeber, 2020, Life sciences.

Crizotinib for c-MET–amplified advanced NSCLC: a single-center experience

B. Oz, M. Yılmaz, D. Tural, 2021, Tumori.

Decrease in estimated glomerular filtration rates in non-small cell lung cancer patients treated with crizotinib

Yakup İriağaç, E. Çavdar, Kubilay Karaboyun, 2022, Journal of Cancer Research and Therapeutics.

Thirty-day mortality rates after immunotherapy initiation.

O. Yazıcı, N. Karadurmuş, S. Kılıçkap, 2021, Immunotherapy.

Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study

M. Yılmaz, D. Tural, F. Selçukbiricik, 2021, Melanoma research.

Ribociclib induced acute kidney injury: A case report

M. Yılmaz, D. Tural, S. Tacar, 2021, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer

Mustafa YILMAZ, D. Tural, S. Tacar, 2022, Istanbul Medical Journal.

Breast cancer in young and very young women; Is age related to outcome?

E. Şeber, T. Yetişyiğit, S. Tacar, 2021, Journal of cancer research and therapeutics.

Lutetium-Associated Myopathy: A Case Report.

M. Yılmaz, D. Tural, S. Tacar, 2022, American Journal of Therapeutics.